### ðŸ«€ Cardiology: Sinus Bradycardia Evaluation

#### âœ… True Statements
1. **Sinus bradycardia** is defined as the presence of **sinus rhythm with a heart rate below 60/min**.
2. **Sinus bradycardia** may be appropriate in **trained athletes** and **during sleep**.
3. **Pathologic sinus node dysfunction** may result from **age-related myocardial fibrosis**, **right coronary ischemia**, **hypothyroidism**, **intracranial hypertension**, **postoperative scarring from cardiothoracic surgery**, or **infiltrative/inflammatory disorders** such as **sarcoidosis**.
4. Common **medication causes** of sinus bradycardia include **Î²-blockers**, **nondihydropyridine calcium channel blockers**, and **donepezil**.
5. **Hypothyroidism** is a **reversible** and important **secondary cause** of sinus bradycardia.
6. Evaluation of **symptomatic bradycardia** should include testing for **thyroid-stimulating hormone** to assess for **hypothyroidism**.
7. **QT prolongation** may be associated with **hypothyroidism**.
8. **Reassurance** is not appropriate for patients with **sinus bradycardia and symptoms** such as **fatigue** or **exercise intolerance**.
9. **Echocardiography** is not indicated in the absence of **signs of structural heart disease** or **heart failure**.
10. **Isolated sinus bradycardia** is an **unusual presentation** of **Lyme disease**, and testing for Lyme is not typically indicated.

#### ðŸ’¬ Extra
1. Some experts propose a threshold of **heart rate <50/min** as a more pragmatic definition for symptomatic bradycardia.
3. These etiologies reflect intrinsic abnormalities affecting the sinus node.
5. Hypothyroidism may present subtly with bradycardia and nonspecific symptoms like fatigue.
6. Thyroid-stimulating hormone testing is warranted in bradycardic patients with unexplained fatigue and exercise intolerance.
7. QT prolongation may not reflect a true prolonged interval due to rate correction errors at low heart rates.
8. A resting sinus rate of 45/min in athletes may be benign, but accompanying symptoms prompt further evaluation.
9. Structural heart disease was deemed unlikely in the described case due to a normal physical exam.
10. Lyme carditis more commonly causes **atrioventricular block** than sinus node dysfunction.

#### ðŸ“‡ Tags
#Cardiology #SinusBradycardia #Hypothyroidism #BradycardiaCauses #BetaBlockers #CalciumChannelBlockers #Donepezil #ThyroidTesting #QTProlongation #LymeDisease

#### ðŸ“š Reference
Kusumoto FM, Schoenfeld MH, Barrett C, et al. 2018 ACC/AHA/HRS guideline on the evaluation and management of patients with bradycardia and cardiac conduction delay: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. *Circulation*. 2019;140:e382-e482. PMID: 30586772 doi:10.1161/CIR.0000000000000628

#### ðŸ†” Question ID
CVMCQ24103

#### ðŸ•’ Last Updated
January 2025

---

#### ðŸ“– Related Text
MKSAP 19: Cardiovascular Medicine â€” Arrhythmias, Approach to the Patient With Bradycardia and Conduction Defects

---

### ðŸ“˜ Related Text Derivations

#### âœ… True Statements
1. **Sinus bradycardia** is defined as the presence of **sinus rhythm with a heart rate below 60/min**, though some experts prefer a threshold of **below 50/min** for symptomatic bradycardia.
2. **Sinus bradycardia** may be appropriate in **trained athletes** and during **sleep**.
3. The most common **extrinsic cause** of sinus bradycardia is **medication use**, particularly **Î²-blockers**, **nondihydropyridine calcium channel blockers**, and **donepezil**.
4. The most frequent **pathologic cause** of sinus bradycardia is **sinus node dysfunction due to age-related myocardial fibrosis**.
5. Additional causes of sinus node dysfunction include **right coronary ischemia**, **hypothyroidism**, **intracranial hypertension**, **postoperative cardiothoracic scarring or fibrosis**, and **infiltrative or inflammatory disorders** such as **sarcoidosis**.

#### ðŸ’¬ Extra
1. The 50â€“60/min heart rate range is rarely symptomatic and may not require further evaluation.
3. These medications suppress sinoatrial node activity through pharmacologic effects on ion channels or autonomic tone.
5. These conditions affect the structural or functional integrity of the sinus node.

#### ðŸ·ï¸ Tags
#Bradycardia #SinusNodeDysfunction #MedicationInducedBradycardia #Fibrosis #Hypothyroidism #Sarcoidosis #RightCoronaryIschemia #IntracranialHypertension #AthleticHeart #CardiothoracicSurgery

---

### ðŸ§¾ Supplemental Tables

<!-- Table: Common Medications That Suppress the Sinoatrial Node -->
<table>
  <caption><strong>Common Medications That Suppress the Sinoatrial Node<sup>a</sup></strong></caption>
  <thead>
    <tr>
      <th>Class</th>
      <th>Examples</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Parasympathomimetic agents</td>
      <td>Donepezil, neostigmine, pyridostigmine</td>
    </tr>
    <tr>
      <td>Sympatholytic drugs</td>
      <td>Î²-Blockers, clonidine</td>
    </tr>
    <tr>
      <td>Opioids and sedatives</td>
      <td>Morphine, fentanyl, midazolam</td>
    </tr>
    <tr>
      <td>Cardiac glycosides</td>
      <td>Digoxin</td>
    </tr>
    <tr>
      <td>Membrane-active antiarrhythmic drugs</td>
      <td>Amiodarone, sotalol, ivabradine</td>
    </tr>
    <tr>
      <td>Nondihydropyridine calcium channel blockers</td>
      <td>Diltiazem, verapamil</td>
    </tr>
  </tbody>
</table>

<p><sup>a</sup>As either a predicted mechanism of drug action or a manifestation of drug toxicity.</p>